Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk

Urology

Volumn 90, Issue , 2016, Pages 148-152

  Klein, Eric A ^a   Haddad, Zaid ^b   Yousefi, Kasra ^b   Lam, Lucia L C ^b   Wang, Qiqi ^b   Choeurng, Voleak ^b   Palmer Aronsten, Beatrix ^b   Buerki, Christine ^b   Davicioni, Elai ^b   Li, Jianbo ^a   Kattan, Michael W ^a   Stephenson, Andrew J ^a   Magi Galluzzi, Cristina ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b GenomeDx Biosciences Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER TISSUE; CLASSIFIER; CONTROLLED STUDY; DECIPHER GENOMIC CLASSIFIER; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEEDLE BIOPSY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; TUMOR BIOPSY; VALIDATION STUDY; GENETICS; GENOMICS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TIME FACTOR;

AGED; BIOMARKERS, TUMOR; BIOPSY, NEEDLE; FOLLOW-UP STUDIES; GENOMICS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TIME FACTORS;

EID: 84977639715     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2016.01.012     Document Type: Article

References (15)

1. 1 Bjartell, A.S., Catto, J.W.F., Eggener, S.E., et al. Genomic predictors of outcome in prostate cancer. Eur Urol 68 (2015), 1033–1044, 10.1016/j.eururo.2015.04.008.
2. 2 Ross, A.E., D'Amico, A.V., Freedland, S.J., Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis, 2015, 10.1038/pcan.2015.31.
3. 3 Ross, A.E., Johnson, M.H., Yousefi, K., et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol 69 (2016), 157–165, 10.1016/j.eururo.2015.05.042.
4. 4 Klein, E.A., Yousefi, K., Haddad, Z., et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol 67 (2015), 778–786, 10.1016/j.eururo.2014.10.036.
5. 5 Epstein, J.I., Allsbrook, W.C., Amin, M.B., Egevad, L.L., The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29 (2005), 1228–1242.
6. 6 Cooperberg, M.R., Hilton, J.F., Carroll, P.R., The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117 (2011), 1–8, 10.1002/cncr.26169.
7. 7 Stephenson, A.J., Scardino, P.T., Eastham, J.A., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23 (2005), 7005–7012, 10.1200/JCO.2005.01.867.
8. 8 Firth, D., Bias reduction of maximum likelihood estimates. Biometrika 80 (1993), 27–38, 10.1093/biomet/80.1.27.
9. 9 Tibshirani, R., The lasso method for variable selection in the Cox model. Stat Med 16 (1997), 385–395.
10. 10 Heagerty, P.J., Lumley, T., Pepe, M.S., Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56 (2000), 337–344, 10.1111/j.0006-341X.2000.00337.x.
11. 11 Klein, E.A., Cooperberg, M.R., Magi-Galluzzi, C., et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 66 (2014), 550–560.
12. 12 Blume-Jensen, P., Berman, D.M., Rimm, D.L., et al. Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res 21 (2015), 2591–2600, 10.1158/1078-0432.CCR-14-2603.
13. 13 Reichard, C.A., Stephenson, A.J., Klein, E.A., Applying precision medicine to the active surveillance of prostate cancer. Cancer 121 (2015), 3403–3411, 10.1002/cncr.29496.
14. 14 Badani, K.K., Kemeter, M.J., Febbo, P.G., et al. The impact of a biopsy based 17-gene genomic prostate score on treatment recommendations in men with newly diagnosed clinically prostate cancer who are candidates for active surveillance. Urol. Pract 2 (2015), 181–189, 10.1016/j.urpr.2014.10.010.
15. 15 Den, R.B., Yousefi, K., Trabulsi, E.J., et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 33 (2015), 944–951, 10.1200/JCO.2014.59.0026.